Company Description
Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States.
The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity, stabilize the first TMT joint, and allow return to weight-bearing in a walking boot; minimally invasive products for four bunion classes; Nanoplasty 3D Minimally Invasive Bunion Correction System delivers a reproducible 3D correction of the bunion deformity through a cosmetically appealing; and Percuplasty Percutaneous 3D Bunion Correction System that provides 3D correction of the bunion deformity through percutaneous incisions.
It also provides Adductoplasty System, a system designed for the correction of metatarsus adductus deformities and osteoarthritis of the midfoot; SpeedMTP Rapid Compression Implant; SpeedPlate Implant Fixation Platform to address the fusion of larger bones of the midfoot and rearfoot; SpeedPlate Micro-Quad implant, an implant designed for stability and fit in small incision surgical approaches; and SpeedAkin Anatomic Compression Implant.
In addition, the company offers The IntelliGuide patient specific instrumentation provides patient-specific, 3D-printed cut guides, and a pre-operative plan for a complete picture of the deformity and correction.
Further, it provides FastGrafter Autografter Harvesting System; SpeedRelease Guided Release Instrument; TriTome Triple-Edge Release Instrument; RazorTome 7mm Precision Osteotome; LapiTome Hooked Bone Removal Osteotome; GreatRelease Rapid MTP Release Instrument; CornerChisel Release Tool; NanoRasp MIS Bone Contouring Tool; FeatherRasp Rapid Bone Contouring Instrument; and Akinator Single-cut Akin Wedge Osteotomy tool.
Additionally, the company offers biologics and wedges, such as Treace Allograft Wedges; and CortiFuse Flowable Cortical Fibers.
Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.
| Country | United States |
| Founded | 2014 |
| IPO Date | Apr 23, 2021 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 450 |
| CEO | John Treace |
Contact Details
Address: 100 Palmetto Park Place Ponte Vedra, Florida 32081 United States | |
| Phone | 904 373 5940 |
| Website | treace.com |
Stock Details
| Ticker Symbol | TMCI |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 1630627 |
| CUSIP Number | 89455T109 |
| ISIN Number | US89455T1097 |
| Employer ID | 47-1052611 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| John T. Treace | Founder, Chairman and Chief Executive Officer |
| Mark L. Hair CPA | Chief Financial Officer |
| Scot M. Elder J.D. | Chief Legal and Compliance Officer and Corporate Secretary |
| Dr. Sean F. Scanlan Ph.D. | Chief Innovation Officer |
| Gaetano M. Guglielmino | Chief Commercial Officer |
| Terry W. Lubben | Chief Operations and Supply Chain Officer |
| Taylor Erickson | Chief Information and Cybersecurity Officer |
| Brad Barr | Senior Vice President of Sales |
| Daniel E. Owens | Chief Human Resources Officer |
| Shana Zink | Senior Vice President of Clinical Affairs and Reimbursement |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 27, 2026 | 10-K | Annual Report |
| Feb 27, 2026 | 8-K | Current Report |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 12, 2026 | SCHEDULE 13G/A | Filing |
| Feb 9, 2026 | SCHEDULE 13G/A | Filing |
| Jan 13, 2026 | 8-K | Current Report |
| Dec 18, 2025 | 8-K | Current Report |
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |
| Nov 12, 2025 | SCHEDULE 13G | Filing |
| Nov 6, 2025 | 10-Q | Quarterly Report |